Incyclix Bio and Lilly to test INX-315 + Verzenio and Fulvestrant in HR+/HER2- Breast Cancer
“We are pleased to enter this clinical trial collaboration with Lilly as it marks another milestone in our commitment to bring INX-315 to patients with advanced cancer,” said Patrick Roberts, Pharm.D., Ph.D., Chief Executive Officer and Co-Founder of Incyclix Bio. “Previous studies of Verzenio plus fulvestrant have demonstrated clinical benefit in patients with HR+, HER2- breast cancer who had disease progression on or after prior treatment with a CDK4/6 inhibitor. We are excited to explore how the addition of our CDK2 inhibitor, INX-315, to this combination can improve clinical outcomes for patients with advanced breast cancer.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000